These results suggest that CD4-IL15/IL15sushi CAR T cells may be a safe and effective treatment for patients with relapsed or refractory T-cell lymphomas, where new treatment options are needed. This evidence concerns the gene IL15 and T-cell non-Hodgkin lymphoma.